Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis

Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis

Abstract Introduction The safety of tofacitinib in psoriatic arthritis (PsA) and rheumatoid arthritis (RA) has been demonstrated in clinical studies of ≤ 4 and 9.5 years, respectively. Post-marketing surveillance (PMS) data for tofacitinib from spontaneous and voluntary adverse event (AE) reports ha...

Deskribapen osoa

Xehetasun bibliografikoak
Egile Nagusiak:	Gerd R. Burmester, Laura C. Coates, Stanley B. Cohen, Yoshiya Tanaka, Ivana Vranic, Edward Nagy, Irina Lazariciu, All-shine Chen, Kenneth Kwok, Lara Fallon, Cassandra Kinch
Formatua:	Artikulua
Hizkuntza:	English
Argitaratua:	Adis, Springer Healthcare 2023-07-01
Saila:	Rheumatology and Therapy
Gaiak:	Post-marketing surveillance Psoriatic arthritis Rheumatoid arthritis Safety Tofacitinib
Sarrera elektronikoa:	https://doi.org/10.1007/s40744-023-00576-8

Antzeko izenburuak

Effectiveness of Tofacitinib in Patients Initiating Therapy for Psoriatic Arthritis: Results from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
nork: Philip J. Mease, et al.
Argitaratua: (2024-01-01)

Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs
nork: Kevin L. Winthrop, et al.
Argitaratua: (2022-12-01)

Psoriatic arthritis - Tofacitinib as a new treatment
nork: Marta Skorupska, et al.
Argitaratua: (2024-06-01)

Risk Stratification of Patients with Psoriatic Arthritis and Ankylosing Spondylitis for Treatment with Tofacitinib: A Review of Current Clinical Data
nork: Lars Erik Kristensen, et al.
Argitaratua: (2024-05-01)

Effect of tofacitinib treatment on active MRI sacroiliitis in psoriatic arthritis patients
nork: E. E. Gubar, et al.
Argitaratua: (2021-05-01)

Tofacitinib in the management of active psoriatic arthritis: patient selection and perspectives
nork: Ly K, et al.
Argitaratua: (2019-08-01)

Safety and Efficacy of Tofacitinib in Patients with Active Psoriatic Arthritis: Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study
nork: Peter Nash, et al.
Argitaratua: (2020-06-01)

Relationships of dermatologic symptoms and quality of life in patients with psoriatic arthritis: analysis of two tofacitinib phase III studies
nork: Peter C. Taylor, et al.
Argitaratua: (2022-07-01)

Efficacy of Tofacitinib for the Treatment of Psoriatic Arthritis: Pooled Analysis of Two Phase 3 Studies
nork: Peter Nash, et al.
Argitaratua: (2018-11-01)

EFFICACY AND SAFETY OF TOFACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS IN REAL CLINICAL PRACTICE
nork: E. Yu. Loginova, et al.
Argitaratua: (2020-06-01)

Efficacy and safety of tofacitinib in an open-label, long-term extension study in patients with psoriatic arthritis who received adalimumab or tofacitinib in a Phase 3 randomized controlled study: a post hoc analysis
nork: Dafna D. Gladman, et al.
Argitaratua: (2024-12-01)

Efficacy of tofacitinib on enthesitis in patients with active psoriatic arthritis: analysis of pooled data from two phase 3 studies
nork: Philip J. Mease, et al.
Argitaratua: (2023-08-01)

Effect of tofacitinib on dactylitis and patient-reported outcomes in patients with active psoriatic arthritis: post-hoc analysis of phase III studies
nork: Ana-Maria Orbai, et al.
Argitaratua: (2022-09-01)

Efficacy of tofacitinib on rheumatoid arthritis: A retrospective single-center cohort study
nork: Yuhui Qi, et al.
Argitaratua: (2023-09-01)

Correction: Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis
nork: Gerd R. Burmester, et al.
Argitaratua: (2023-12-01)

NEW APPROACHES TO PHARMACOTHERAPY OF RHEUMATOID ARTHRITIS: TOFACITINIB
nork: E. L. Nasonov
Argitaratua: (2014-06-01)

Impact of tofacitinib on patient-reported outcomes in patients with psoriatic arthritis. Data from the real clinical practice
nork: L. D. Vorobyeva, et al.
Argitaratua: (2022-07-01)

A Case Series Report on the Effect of Tofacitinib on Joint Inflammation and Gut Microbiota Composition in Psoriatic Arthritis Patients Naive to Biologic Agents
nork: Andrea Picchianti Diamanti, et al.
Argitaratua: (2024-11-01)

Cardiovascular risk factors in psoriatic and rheumatoid arthritis
nork: Andrey Petrovich Rebrov, et al.
Argitaratua: (2011-05-01)

IS PSORIATIC ARTHRITIS REALLY PSORIATIC?
nork: Sh. F. Erdes
Argitaratua: (2014-12-01)

Efficacy and safety of JAK inhibitors in the treatment of psoriasis and psoriatic arthritis: a systematic review and meta-analysis
nork: Samantha Sarabia, et al.
Argitaratua: (2022-09-01)

THE PLACE OF TOFACITINIB IN THE TREATMENT STRATEGY OF RHEUMATOID ARTHRITIS
nork: V. I. Mazurov, et al.
Argitaratua: (2018-05-01)

Difficult-to-treat psoriatic arthritis. Data from the All-Russian registry of patients with psoriatic arthritis
nork: E. Yu. Loginova, et al.
Argitaratua: (2024-10-01)

Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo
nork: Dafna D. Gladman, et al.
Argitaratua: (2022-02-01)

Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study
nork: Jürgen Wollenhaupt, et al.
Argitaratua: (2019-04-01)

Synovial Immunohistological Biomarkers of the Classification of Undifferentiated Arthritis Evolving to Rheumatoid or Psoriatic Arthritis
nork: Andrea Cuervo, et al.
Argitaratua: (2021-04-01)

Experience with tofacitinib in the treatment of resistant rheumatoid arthritis
nork: A. R. Babaeva, et al.
Argitaratua: (2015-06-01)

Nail disease in psoriatic arthritis. Data from the Russian Psoriatic Arthritis Registry
nork: E. E. Gubar, et al.
Argitaratua: (2021-10-01)

Efficacy and Safety of Tofacitinib in Patients with Psoriatic Arthritis or Ankylosing Spondylitis by Cigarette Smoking Status
nork: Alexis Ogdie, et al.
Argitaratua: (2024-09-01)

Enhanced angiogenic function in response to fibroblasts from psoriatic arthritis synovium compared to rheumatoid arthritis
nork: S. Fromm, et al.
Argitaratua: (2019-12-01)

Comparing Bone Mineral Density in Rheumatoid Arthritis and Psoriatic Arthritis
nork: Fatemeh Shirani, et al.
Argitaratua: (2021-09-01)

Evaluation of diagnostic and therapeutic delay in patients with rheumatoid arthritis and psoriatic arthritis
nork: M. Iacovantuono, et al.
Argitaratua: (2024-03-01)

Co-Delivery of Loxoprofen and Tofacitinib by Photothermal Microneedles for Rheumatoid Arthritis Treatment
nork: Yi Lu, et al.
Argitaratua: (2023-05-01)

Blocking Jak/STAT signalling using tofacitinib inhibits angiogenesis in experimental arthritis
nork: Paola Di Benedetto, et al.
Argitaratua: (2021-08-01)

CLINICAL PRESENTATION OF PSORIATIC ARTHRITIS AND RHEUMATOID ARTHRITIS IN EARLY STAGES - SIMILARITIES AND DIFFERENCES IN DIAGNOSIS
nork: Eugeniu Russu, et al.
Argitaratua: (2023-04-01)

Clinical and instrumental characteristics of axial psoriatic arthritis in combination with hyperuricemia
nork: Yu. L. Korsakova, et al.
Argitaratua: (2024-08-01)

Fibromyalgia with psoriatic and rheumatoid arthritis: relationship with disease activity and serum vitamin D level
nork: Hanan S. Abozaid, et al.
Argitaratua: (2023-07-01)

The Role of Structured Musculoskeletal Ultrasound in the Early Diagnosis of Rheumatoid Arthritis and Psoriatic Arthritis Patients: Correlation with Clinical Disease Activity Scores
nork: Eman Abdel Ghani Sayed Mahmoud*
Argitaratua: (2024-07-01)

Psoriatic arthritis: imaging techniques
nork: E. Lubrano, et al.
Argitaratua: (2012-06-01)

Content validity and psychometric evaluation of Functional Assessment of Chronic Illness Therapy-Fatigue in patients with psoriatic arthritis
nork: David Cella, et al.
Argitaratua: (2019-05-01)